2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations

2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations

The liver is the primary metabolic factory and clearance organ for anesthetic drugs. It plays a central role in protein synthesis (albumin, clotting factors, pseudocholinesterase), glucose homeostasis, bile formation, and waste detoxification. Advanced liver disease alters anesthetic pharmacokinetics via impaired drug metabolism, reduced plasma protein binding, altered volume of distribution, and complex multi-organ derangements including cirrhotic cardiomyopathy, portopulmonary hypertension, hepatopulmonary syndrome, and hepatorenal syndrome.

---

1. Hepatic Microcirculation & Dual Blood Supply

The liver receives 1,500 mL/min of blood, accounting for approximately 25% of resting cardiac output, but represents only 2.5% of total body weight.

                              DUAL HEPATIC BLOOD SUPPLY

            PORTAL VEIN (~1,050-1,125 mL/min)        HEPATIC ARTERY (~375-450 mL/min)
            • 70% to 75% of Total Blood Flow         • 25% to 30% of Total Blood Flow
            • 50% to 55% of Oxygen Supply            • 45% to 50% of Oxygen Supply
            • Low Pressure (7 - 10 mmHg)             • High Pressure (Systemic MAP ~90 mmHg)
            • Venous drainage from stomach, spleen,  • Direct celiac axis / common hepatic
              pancreas, and intestines                 artery branch
                                  │                        │
                                  └───────────┬────────────┘
                                              ▼
                                   Hepatic Sinusoids
                          • Low-pressure capillary network
                          • Lined by fenestrated endothelial cells
                          • Space of Disse (lymph formation & protein exchange)
                          • Kupffer Cells (tissue macrophages)
                                              │
                                              ▼
                                     Central Veins
                                              │
                                              ▼
                                     Hepatic Veins
                                              │
                                              ▼
                                   Inferior Vena Cava (IVC)

The Hepatic Arterial Buffer Response (HABR)

The Hepatic Arterial Buffer Response (HABR) is an intrinsic, semi-autonomous compensatory mechanism that maintains constant total hepatic blood flow. It operates in the microscopic space of Mall surrounding the hepatic triad:

• Mechanism: Adenosine is constantly produced at a steady rate by periportal tissues and washed away into portal venous blood. If portal vein blood flow decreases (e.g., surgical retraction, laparoscopy, hypotension, splanchnic pooling), local adenosine washout decreases. Accumulated adenosine acts on vascular purinergic A2 receptors on hepatic arterioles, inducing potent hepatic arterial vasodilation and restoring total hepatic blood flow and oxygen delivery.
• Unidirectional Limitation: The HABR is strictly unidirectional: a decrease in portal vein flow increases hepatic arterial flow, but changes in hepatic arterial flow do not alter portal venous flow!
• Anesthetic Blunting: Volatile anesthetics (especially halothane > isoflurane > sevoflurane/desflurane) and severe cirrhotic endotoxemia blunt the HABR, rendering the liver vulnerable to ischemic injury during intraoperative hypotension.

---

2. Hepatic Drug Clearance & Extraction Ratio

Hepatic clearance ($Cl_H$) represents the volume of blood cleared of drug by the liver per unit of time:

$Cl_H = Q_H \times E_H = Q_H \times \left( \frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}} \right)$

• $Q_H$ = Total hepatic blood flow (~1,500 mL/min).
• $E_H$ = Hepatic Extraction Ratio (fraction of drug removed across a single pass through the liver; range 0.0 to 1.0).
• $C_{\text{in}}$ and $C_{\text{out}}$ = Inflow and outflow drug concentrations.

High vs. Low Extraction Ratio Drugs

---

3. Biotransformation: Phase I vs. Phase II Metabolism

                               DRUG BIOTRANSFORMATION

   Lipophilic Parent Drug
             │
             ▼ Phase I Functionalization (CYP450 Superfamily, SER)
   • Oxidation (Hydroxylation, Dealkylation, Deamination)
   • Reduction
   • Hydrolysis
   * Introduces or unmasks a polar functional group (-OH, -NH2, -SH, -COOH)
   * Vulnerable to aging, cirrhosis, and enzyme induction / inhibition
             │
             ▼ Intermediate Metabolite (Active, Inactive, or Toxic)
             │
             ▼ Phase II Conjugation (Cytosolic & Luminal Transferases)
   • Glucuronidation (UDP-glucuronosyltransferase / UGT)
   • Sulfation (Sulfotransferase)
   • Glutathione conjugation (GST)
   • Acetylation (NAT)
   * Couples a large hydrophilic endogenous substrate to form polar, water-soluble excretable product
   * Relatively preserved in aging and moderate cirrhosis
             │
             ▼
   Hydrophilic Excretable Metabolite (Excreted in Bile or Urine)

Cytochrome P450 Isoenzymes & Anesthetic Interactions

Acetaminophen Toxicity & N-Acetylcysteine (NAC) Rescue

• Under normal conditions, 90% to 95% of acetaminophen undergoes Phase II glucuronidation and sulfation to non-toxic conjugates.
• The remaining 5% to 10% is metabolized via CYP2E1 to the highly reactive, electrophilic, hepatotoxic intermediate NAPQI (N-acetyl-p-benzoquinone imine).
• NAPQI is rapidly detoxified by conjugation with endogenous Glutathione to form non-toxic mercapturic acid.
• In acetaminophen overdose (>7.5-10 g in adults) or in chronic alcoholics with induced CYP2E1 and depleted glutathione stores: Glutathione is exhausted (>70% depletion) $\rightarrow$ excess unbound NAPQI binds covalently to cysteinyl sulfhydryl groups of hepatocellular proteins $\rightarrow$ mitochondrial permeability transition, ATP collapse, and centrilobular (Zone 3) hepatic necrosis.
• Antidote: N-Acetylcysteine (NAC) restores hepatic glutathione stores and acts as a direct sulfhydryl surrogate to bind and neutralize NAPQI. Most effective when administered within 8 hours of ingestion.

---

4. Cirrhosis, Scoring Systems & Pathophysiologic Derangements

Child-Turcotte-Pugh (CTP) vs. MELD Scoring

CHILD-PUGH CLASSIFICATION (Mnemonic: "Pour Another Beer At Eleven")
Parameters: PT/INR, Ascites, Bilirubin, Albumin, Encephalopathy

• Class A (5 - 6 Points): Well-compensated disease (Perioperative mortality <10%)
• Class B (7 - 9 Points): Significant functional impairment (Perioperative mortality ~30%)
• Class C (10 - 15 Points): Decompensated end-stage cirrhosis (Perioperative mortality 70-80%; elective surgery contraindicated)

• MELD-Na Score: Utilizes objective continuous laboratory variables: Serum Bilirubin, Serum Creatinine, INR, and Serum Sodium. MELD score ranges from 6 to 40. A MELD score $>15$ is associated with significant perioperative morbidity and mortality; elective surgery is generally avoided when MELD $>20$.

Multi-Organ Manifestations of Cirrhosis

                        CIRRHOTIC MULTI-ORGAN CASCADE

                             Portal Hypertension
                                      │
                                      ▼
                  Massive Splanchnic Endothelial NO Release
                                      │
                                      ▼
                      Profound Splanchnic Vasodilation
                                      │
       ┌──────────────────────────────┴──────────────────────────────┐
       ▼                                                             ▼
Marked Drop in SVR (Hyperdynamic State)             Severe Effective Arterial Underfilling
• Elevated resting Cardiac Output (CO)              • Baroreceptor unloading
• Low MAP & widened pulse pressure                  • Intense RAAS & Sympathetic activation
• Cirrhotic Cardiomyopathy (blunted inotropic       • High non-osmotic ADH release
  response to stress, diastolic dysfunction,                  │
  prolonged QTc)                                              ▼
                                                    Avid Renal Na+ / H2O Retention
                                                    • Refractory Ascites & Hyponatremia
                                                    • Extreme Renal Vasoconstriction
                                                              │
                                                              ▼
                                                    Hepatorenal Syndrome (HRS-AKI)

Pulmonary & Renal Complications in Liver Disease

1. Hepatopulmonary Syndrome (HPS):
   • Triad: Advanced liver disease/portal hypertension, Intrapulmonary Vascular Dilatations (IPVDs), and Arterial Hypoxemia (widened $\text{P}_{\text{A-a}}\text{O}_2 > 15\text{ mmHg}$). Dilated precapillary and capillary vessels allow unoxygenated mixed venous blood to pass without full diffusion of oxygen (functional intrapulmonary shunt).
   • Hallmark Symptoms: Platypnea (dyspnea worsened in the upright position) and Orthodeoxia (arterial deoxygenation worsened in the upright position) due to gravitational pooling of blood to dilated bases.
   • Diagnostic Gold Standard: Contrast-Enhanced Transthoracic Echocardiography (Bubble Study): Agitated saline injected intravenously. Appearance of microbubbles in the left atrium after 3 to 6 cardiac cycles confirms transpulmonary shunting (appearance in 1-2 cycles indicates intracardiac right-to-left shunt like PFO).
2. Portopulmonary Hypertension (POPH):
   • Pulmonary arterial hypertension occurring in patients with portal hypertension: Mean Pulmonary Artery Pressure (mPAP) $\ge 20-25\text{ mmHg}$, Pulmonary Vascular Resistance (PVR) $> 3\text{ Wood units}$ ($> 240\text{ dyn}\cdot\text{s}/\text{cm}^5$), and Pulmonary Capillary Wedge Pressure (PCWP) $\le 15\text{ mmHg}$.
   • Critical Warning: Severe POPH (mPAP $> 45-50\text{ mmHg}$) carries $>50%$ perioperative mortality and is an absolute contraindication to liver transplantation and elective surgery unless optimized with targeted pulmonary vasodilators (e.g., Epoprostenol, Sildenafil).
3. Hepatorenal Syndrome (HRS-AKI):
   • Functional oliguric renal failure resulting from severe splanchnic vasodilation causing intense renal vasoconstriction and cortical ischemia in histologically normal kidneys.
   • Diagnostic Criteria: Cirrhosis with ascites, AKI by KDIGO criteria, no response after >=48 hours of diuretic withdrawal and volume expansion with IV Albumin (1 g/kg/day, max 100 g/day), absence of shock, no recent nephrotoxic exposures, and absence of macroscopic structural renal disease (proteinuria $<500\text{ mg/day}$, absence of microhematuria, normal renal ultrasound).
   • Medical Management: Terlipressin (selective V1a vasopressin receptor agonist) or Norepinephrine infusion plus IV Albumin (20-40 g/day) to induce splanchnic vasoconstriction, increase effective circulating volume, and restore renal perfusion pressure. Definitive cure is orthotopic liver transplantation.

---

5. Gastrointestinal Motility, Aspiration Pathophysiology & Prophylaxis

Mendelson's Syndrome & Aspiration Criteria

Pulmonary aspiration of gastric contents is a life-threatening anesthesia crisis. In 1946, Curtis Mendelson established the classical risk criteria for chemical pneumonitis:

• Critical Gastric Volume: $> 25\text{ mL}$ (or $> 0.4\text{ mL/kg}$).
• Critical Gastric pH: $< 2.5$.

                     ASPIRATION PNEUMONITIS PATHOGENESIS

   Aspiration of Gastric Acid (pH <2.5) + Particulate Food Matter
                                 │
                                 ▼
   Direct Chemical Burn to Tracheobronchial Mucosa (<5 minutes)
                                 │
                                 ▼
   Destruction of Type I/II Alveolocytes & Capillary Endothelial Denudation
                                 │
                                 ▼
   Massive Influx of Neutrophils, Cytokines (TNF-alpha, IL-8), & Plasma Exudation
                                 │
                                 ▼
   Alveolar Edema, Loss of Surfactant, Atelectasis, Severe Bronchospasm
                                 │
                                 ▼
   Acute Respiratory Distress Syndrome (ARDS) & Intractable Hypoxemia

High-Risk Patient Populations for Aspiration

• Emergency surgical cases (non-fasting / full stomach).
• Pregnancy (elevated progesterone decreases lower esophageal sphincter [LES] tone; gravid uterus displaces stomach cranially and horizontally; elevated gastrin increases acidity; considered full stomach $\ge 12\text{ weeks}$ gestation through 48 hours postpartum).
• Diabetes Mellitus with Autonomic Neuropathy (Gastroparesis).
• Bowel obstruction, ileus, acute peritonitis, active trauma / pain (sympathetic surge halts gastric emptying).
• Hiatal hernia, severe GERD, morbid obesity ($\uparrow$ intra-abdominal pressure).
• Opioid administration (profoundly delays gastric emptying).
• GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide): Profound delayed gastric emptying. ASA Consensus Guidance: For elective procedures, hold weekly GLP-1 agonists for 1 week prior to surgery, and daily formulations on the morning of surgery. If significant GI symptoms (nausea, vomiting, abdominal distension, severe reflux) persist on day of surgery, delay elective surgery or evaluate gastric volume via bedside Point-of-Care Ultrasound (POCUS) and proceed with Rapid Sequence Induction (RSI).

Pharmacologic Aspiration Prophylaxis